CN1226036C - 用于治疗或预防精神病的、米尔塔扎平和抗精神病药的药物组合物 - Google Patents

用于治疗或预防精神病的、米尔塔扎平和抗精神病药的药物组合物 Download PDF

Info

Publication number
CN1226036C
CN1226036C CNB98803770XA CN98803770A CN1226036C CN 1226036 C CN1226036 C CN 1226036C CN B98803770X A CNB98803770X A CN B98803770XA CN 98803770 A CN98803770 A CN 98803770A CN 1226036 C CN1226036 C CN 1226036C
Authority
CN
China
Prior art keywords
mirtazapine
antipsychotic
psychosis
haloperidol
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB98803770XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1251526A (zh
Inventor
C·L·E·布罗坎普
H·H·G·伯兰德森
R·M·宾德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of CN1251526A publication Critical patent/CN1251526A/zh
Application granted granted Critical
Publication of CN1226036C publication Critical patent/CN1226036C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB98803770XA 1997-03-27 1998-03-25 用于治疗或预防精神病的、米尔塔扎平和抗精神病药的药物组合物 Expired - Fee Related CN1226036C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97200881 1997-03-27
EP97200881.7 1997-09-11
EP97202785.8 1997-09-11
EP97202785 1997-09-11

Publications (2)

Publication Number Publication Date
CN1251526A CN1251526A (zh) 2000-04-26
CN1226036C true CN1226036C (zh) 2005-11-09

Family

ID=26146283

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB98803770XA Expired - Fee Related CN1226036C (zh) 1997-03-27 1998-03-25 用于治疗或预防精神病的、米尔塔扎平和抗精神病药的药物组合物

Country Status (24)

Country Link
EP (1) EP0969845B1 (enExample)
JP (2) JP4377456B2 (enExample)
KR (1) KR100577865B1 (enExample)
CN (1) CN1226036C (enExample)
AR (1) AR012193A1 (enExample)
AT (1) ATE318604T1 (enExample)
AU (1) AU726194B2 (enExample)
BR (1) BR9808077A (enExample)
CA (1) CA2284551C (enExample)
CZ (1) CZ298105B6 (enExample)
DE (1) DE69833645T2 (enExample)
DK (1) DK0969845T3 (enExample)
ES (1) ES2259207T3 (enExample)
HU (1) HUP0002742A3 (enExample)
ID (1) ID22283A (enExample)
IL (1) IL123716A (enExample)
NO (1) NO994673L (enExample)
NZ (1) NZ337618A (enExample)
PL (1) PL191449B1 (enExample)
PT (1) PT969845E (enExample)
RU (1) RU2222330C2 (enExample)
TR (1) TR199902334T2 (enExample)
TW (1) TW587938B (enExample)
WO (1) WO1998043646A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
FR2797399B1 (fr) * 1999-08-13 2002-10-18 Aventis Pharma Sa Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines
US6350773B1 (en) 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
FR2802101B1 (fr) * 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
HUP0204050A3 (en) * 2000-01-19 2004-09-28 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
JP2004518699A (ja) 2001-02-06 2004-06-24 アストラゼネカ・アクチエボラーグ クエチアピンを用いた物質乱用の治療方法
EP1795199A3 (en) * 2001-02-06 2007-07-25 AstraZeneca AB Quetiapine for the treatment of substance dependence or substance abuse
RU2232574C2 (ru) * 2002-04-05 2004-07-20 Новосибирский институт органической химии им. Н.Н.Ворожцова СО РАН Лекарственное средство для лечения различных форм депрессий "флуоглизин"
US20050095292A1 (en) 2003-10-29 2005-05-05 Wyeth Sustained release pharmaceutical compositions
DK1541197T3 (da) * 2003-12-02 2009-06-15 Pharmaneuroboost N V Anvendelse af pipamperon og en SNDRI, SNRI eller SSRI til behandling af humörsvingninger eller angstlidelser
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1547650A1 (en) * 2003-12-02 2005-06-29 B & B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CN1968706A (zh) 2004-06-03 2007-05-23 霍夫曼-拉罗奇有限公司 用顺铂和egfr－抑制剂治疗
JP5001271B2 (ja) * 2006-06-09 2012-08-15 大日本住友製薬株式会社 新規テープ製剤
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
DE102012011839B4 (de) * 2012-06-14 2018-03-22 Norbert Müller Verwendung von Interferon-gamma in einem Verfahren zur Behandlung von psychiatrischen Erkrankungen
RU2509560C1 (ru) * 2013-03-22 2014-03-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые терапевтические комбинации миртазапина для применения при болевых расстройствах

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2410821A1 (de) * 1974-03-07 1975-09-18 Hoechst Ag Pharmazeutische kombinationspraeparate mit psychotroper wirkung und verfahren zu ihrer herstellung
CA1327008C (en) * 1988-01-15 1994-02-15 Walter Merz Anti-psychotic imidazobenzodiazepine
EP0431663B1 (en) * 1989-12-06 1994-01-12 Akzo Nobel N.V. Stabilized solutions of psychotropic agents
FI111367B (fi) * 1991-02-04 2003-07-15 Aventis Pharma Inc Menetelmä terapeuttisesti käyttökelpoisten N-(aryylioksialkyyli)heteroaryyli-8-atsabisyklo[3.2.1]oktaanijohdannaisten valmistamiseksi ja menetelmässä käytetyt välituotteet
ZA935078B (en) * 1992-07-15 1994-02-07 Nicolaas Johannes Jaco Loetter Pharmaceutical composition
RU2062114C1 (ru) * 1992-09-30 1996-06-20 Московский научно-исследовательский институт психиатрии МЗ РФ Способ лечения эндогенных психозов
PT669128E (pt) * 1992-11-17 2000-06-30 Yoshitomi Pharmaceutical Micro-esfera de libertacao sustentada contendo antipsicoticos e processo para produzir a mesma
JPH07242669A (ja) * 1994-03-07 1995-09-19 Akikazu Ogawa 四環系とブチロフェノン誘導体を化学結合した化合物

Also Published As

Publication number Publication date
KR20010005677A (ko) 2001-01-15
HUP0002742A2 (hu) 2001-05-28
ID22283A (id) 1999-09-30
IL123716A0 (en) 1998-12-06
NZ337618A (en) 2000-06-23
AR012193A1 (es) 2000-09-27
NO994673D0 (no) 1999-09-24
PT969845E (pt) 2006-05-31
PL335890A1 (en) 2000-05-22
RU2222330C2 (ru) 2004-01-27
CZ298105B6 (cs) 2007-06-27
CA2284551C (en) 2007-06-12
CA2284551A1 (en) 1998-10-08
BR9808077A (pt) 2000-03-08
CN1251526A (zh) 2000-04-26
KR100577865B1 (ko) 2006-05-10
TW587938B (en) 2004-05-21
EP0969845A1 (en) 2000-01-12
ES2259207T3 (es) 2006-09-16
EP0969845B1 (en) 2006-03-01
TR199902334T2 (xx) 2000-01-21
DE69833645T2 (de) 2006-08-24
NO994673L (no) 1999-11-17
JP2009280596A (ja) 2009-12-03
IL123716A (en) 2001-03-19
AU7213998A (en) 1998-10-22
HUP0002742A3 (en) 2003-03-28
DK0969845T3 (da) 2006-06-19
PL191449B1 (pl) 2006-05-31
CZ343199A3 (cs) 2000-04-12
WO1998043646A1 (en) 1998-10-08
ATE318604T1 (de) 2006-03-15
DE69833645D1 (de) 2006-04-27
AU726194B2 (en) 2000-11-02
JP4377456B2 (ja) 2009-12-02
JP5023315B2 (ja) 2012-09-12
HK1023293A1 (en) 2000-09-08
JP2001521497A (ja) 2001-11-06

Similar Documents

Publication Publication Date Title
CN1226036C (zh) 用于治疗或预防精神病的、米尔塔扎平和抗精神病药的药物组合物
US6150353A (en) Therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
US6444665B1 (en) Method for treating pain
JPS6143112A (ja) 精神性欲機能障害治療剤
US5447948A (en) Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
CN1235545A (zh) 含有氯雷他定和减充血剂的用于治疗哮喘的组合物
MXPA02007095A (es) Combinacion de farmacos para el tratamiento de la depresion y desordenes relacionados que comprenden mirtazapina.
CN1176652C (zh) 褪黑激素在治疗疾病方面的应用
MX2014002125A (es) Tratamiento de sintomas asociados a gastroparesia femenina.
US4886815A (en) Treatment and prevention of retinal edema with dopaminergic antagonists
HUP0200655A2 (hu) Osanetant alkalmazása kedélyállapot-rendellenességek kezelésére használható gyógyszerek előállítására
HK1023293B (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
MXPA99008791A (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
WO2002062346A1 (en) Method of treating substance abuse with quetiapine
US4886795A (en) Treatment and prevention of retinal edema with dopaminergic antagonists
EP1901726A2 (en) Composition for treatment of psychosis
US4624957A (en) Treatment and prevention of retinal edema with dopaminergic antagonists
HK1009400B (en) Combination drug containing tramadol and a calcium channel antagonist
HK1009400A1 (en) Combination drug containing tramadol and a calcium channel antagonist
EP1795199A2 (en) Quetiapine for the treatment of substance dependence or substance abuse
HK1104785A (en) Quetiapine for the treatment of substance dependence or substance abuse

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ORGANON NV

Free format text: FORMER OWNER: AKZO NOVEL N.V. CORP.

Effective date: 20070105

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20070105

Address after: Holland

Patentee after: Organon NV

Address before: Holland Arnhem

Patentee before: Akzo Nobel N. V.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051109